Clinical Trial

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 21, 2023 (before its estimated March 8, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
Trial Details
NCT Number NCT06044077
Lead Sponsor Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Conditions Pneumococcal Disease
Enrollment 1,920 participants
Start Date 2023-09-08
Primary Completion 2024-03-08 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-21